Within a three-day period, Phathom Pharmaceuticals achieves dual FDA approvals for Voquezna, its groundbreaking heartburn medication. The first approval on 30 October involves the reformulation of Voquezna to address Helicobacter pylori infection, followed by a second approval on 01 November for treating gastroesophageal reflux disease erosive esophagitis (erosive GERD) and associated heartburn.
The recent FDA approval heralds a monumental leap in the US erosive GERD treatment landscape, which hadn’t seen substantial innovation for over 30 years. Within a single week, Phathom managed to secure two approvals for the same compound—a rare occurrence. Voquezna initiall...
